2017 ASCO Meeting Highlights in Pancreatic Cancer


CanStem111P trial
Tanios Bekaii-Saab, MD

Begin


A phase Ib/II study of cancer stemness inhibitor napabucasin (BBI-608)
Tanios Bekaii-Saab, MD

Begin


Results of the phase III ESPAC-4 study
Alok A. Khorana, MD

Begin


Results of phase II portion of NRG Oncology/RTOG 0848
Randomized phase II study of 2nd-line FOLFIRI versus modified FOLFIRI with PARP inhibitor ABT-888 (veliparib)
Randomized phase II study of PEGPH20 plus PAG vs AG

Philip A. Philip, MD

Begin


Second-line treatment in patients with pancreatic ductal adenocarcinoma
Ramesh Ramanathan, MD

Begin


Nomogram for predicting overall survival (OS) in patients (pts) treated with nab-P plus Gem or Gem alone
Ramesh Ramanathan, MD

Begin


Randomized phase II study of PEGPH20 plus nab-paclitaxel/gemcitabine (PAG) vs AG
Andrea Wang-Gillam, MD

Begin

Partners in Pancreatic Cancer would like to recognize and thank Celgene Corporation
for their educational support of PartnersinPancreaticCancer.com.

©2017 MediCom Worldwide, Inc. All rights reserved